XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Stock-Based Compensation
6 Months Ended
Jun. 30, 2024
Stock-Based Compensation  
Stock-Based Compensation

(8)  Stock-Based Compensation

A summary of stock option activity for the six months ended June 30, 2024 is as follows:

Weighted

Weighted

Average

Average

Exercise

Remaining

Price

Contractual

    

Shares

    

Per Share

    

Term (In Years)

Options outstanding at December 31, 2023

 

6,378,924

$

29.69

7.5

Granted

 

1,818,160

$

36.50

Exercised

 

(592,738)

$

12.50

Canceled

 

(71,123)

$

165.60

Options outstanding at June 30, 2024

 

7,533,223

$

31.41

7.8

Options vested and expected to vest at June 30, 2024

 

7,364,743

$

31.33

7.8

Options exercisable at June 30, 2024

 

3,552,278

$

29.05

6.5

Shares available for grant under the Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (as amended, effective as of June 13, 2024)

 

2,466,466

The weighted average grant-date fair value of stock options granted during the three and six months ended June 30, 2024 was $26.41 and $26.42, respectively.

The aggregate intrinsic value of stock options vested and expected to vest at June 30, 2024 was $82.5 million. The aggregate intrinsic value of stock options exercisable at June 30, 2024 was $61.2 million. As of June 30, 2024, total compensation cost related to non-vested employee, consultant and non-employee director stock options not yet recognized was approximately $93.1 million, net of estimated forfeitures, which is expected to be recognized as expense over a weighted average period of 2.9 years.

Stock-based compensation expense for the three and six months ended June 30, 2024 and 2023 was recorded as follows:

Three Months Ended June 30, 

Six Months Ended June 30, 

    

2024

    

2023

    

2024

    

2023

(In thousands)

(In thousands)

Research and development

$

3,884

$

2,489

$

7,577

$

4,650

General and administrative

 

3,756

 

2,728

 

7,265

 

4,907

Total stock-based compensation expense

$

7,640

$

5,217

$

14,842

$

9,557

The fair values of employee, consultant and non-employee director stock options granted during the three and six months ended June 30, 2024 and 2023 were valued using the Black-Scholes option pricing model with the following assumptions:

Three Months Ended June 30, 

Six Months Ended June 30, 

    

    

2024

    

2023

    

2024

    

2023

Expected stock price volatility

 

82 – 93%

92%

82 – 93%

92%

Expected option term

 

6.0 Years

6.0 Years

6.0 Years

6.0 Years

Risk-free interest rate

 

4.2 – 4.5%

3.5 – 3.9%

4.0 – 4.5%

3.5 – 4.0%

Expected dividend yield

 

None

None

None

None